Evaluation of the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (C-G) formulas in the Calvert equation for Carboplatin Dosing Whitney.

Slides:



Advertisements
Similar presentations
Assesment of renal function in case of near normal creatinine (<1
Advertisements

Chronic Kidney Disease/Dialysis Belinda Jim, MD January 15, 2009.
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Estimation of Sample Size
CREATININE AND CYSTATIN-C BASED GFRs VS 51 Cr-EDTA GFR IN PATIENTS WITH DECOMPENSATED CIRRHOSIS 1 4th Department of Internal Medicine, Hippokration General.
Clinical Pharmacist Intervention in Cardiac Patients With Renal Impairment Elham Al-Shammari, B.Sc. Pharm. Hisham Abou-Auda, Ph. D. Meshal Al-Mutairi,
Kidney Function Tests Rana Hasanato, MD, KSFCB
Giving Induction Radiation in Addition to Chemotherapy Is Not Associated with Improved Survival of NSCLC Patients with Operable Mediastinal Nodal Disease.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Serum Creatinine and eGFR Where Are We Now? Dr Mike Bosomworth Lead Clinician - Blood Sciences Leeds Teaching Hospitals 16 th April
Estimated GFR Based on Creatinine and Cystatin C
Early detection of CKD CKD: Its out there somewhere.
Health Care Costs Associated with Chronic Kidney Disease in Patients with Type II Diabetes Zita Shiue, MD Internal Medicine, R3 Chief of Medicine Conference.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Katherine Gerrald, PharmD Candidate 1 ; Anne Hishon, PharmD Candidate 1 ; P. Brandon Bookstaver, PharmD, BCPS 2 1 University of South Carolina, College.
PREDICTING AKI IS MORE CHALLENGING AS AGE PROGRESSES Sandra Kane-Gill, PharmD, MSc Associate Professor, School of Pharmacy.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
*Jamal S Al Wakeel M.D., *Durdana Hammad M.D., *Abdul Karaem Al Suwaida M.D., *Nauman Tarif M.D., ♦ AbdulRauf Chaudhary, ♦ Arthur Isnani M.D., ♠ Waleed.
Comparison of Blood Pressure Lowering with Hydrochlorothiazide and Chlorthalidone Kurt A. Wargo, Pharm.D., BCPS, Thomas M. English, Ph.D., Anna J. Aaron,
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
Section 2: Detection of CKD. What Tests Are Available? Direct GFR measurement –Inulin clearance –Radionuclides –Iohexol clearance 3 hr CrCl with Cimetidine.
Mrs. Watcharasa Pitug ID The Association between Waist Circumference and Renal Insufficiency among Hypertensive Patients 15/10/58 1.
Estimation of Kidney Function Richard C. Walls
Changes in Renal Function in Patients Treated with Tenofovir DF (TDF) Compared to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Joel E. Gallant,
Warfarin Efficacy in Cancer Patients on Long-term Anticoagulation Neha Doshi, PharmD Candidate LeAnn B. Norris, PharmD, BCPS P. Brandon Bookstaver, PharmD,
Dosing Regimen Individualization Body Size Variability in Body Size Does one size fit all ? If body size is outside the range  25% of normal (for 70.
Background  Obesity is defined as a body mass index (BMI) ≥30 kg/m 2  33 states have a prevalence of obesity 25% or greater  Evidence illustrates that.
2-4. Estimated Renal Function Estimated GFR = 1.8 x (Cs) x (age) Cockcroft-Gault eq. – Estimated creatine clearance (mL/min) = (140 – age x body weight,
Interobserver Reliability of Acute Kidney Injury Network (AKIN) criteria A single center cohort study Figure 2 The acute kidney injury network (AKIN) criteria.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Pharmacokinetics of Vancomycin in Adult Oncology Patients Hadeel Al-Kofide MS.c; Iman Zaghloul PhD; and Lamya Al-Naim PharmD Department of Clinical Pharmacy,
Differences in Pulsatile vs. Continuous-Flow Left Ventricular Assist Devices on Renal Function Antone Tatooles, MD; Laura A. Coyle, MSN, ACNP-BC; Colleen.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
What is the Best Formula to Estimate GFR in Renal Allograft? Presenter: Ammar Qutub Supervisor: Prof.Abdallah Sayyari KSAU-HS College of Medicine.
Table 1. Clinical characteristics of subjects Mean ± s.d. n1363 Age (years)55.6 ± 14.1 Genders, % Males49.1 Females50.9 Diabetes, %44.9 Hypertension, %14.0.
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
Optimum Re 2015 Charlotte A. Lee, M.D., FLIM, DBIM EVALUATING RENAL FUNCTION.
ALLIE PUNKE PHARMCOKINETICS. KIDNEY FUNCTION FOR DRUG DOSING.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
Are prediction equations for glomerular filtration rate useful for the long-term monitoring of type 2 diabetic patients? Ne´ stor Fontsere´, Isabel Salinas,
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Choice of Estimated Glomerular Filtration Rate Equation.
Charles Oo / ASCPT March 06 1 Repeated evaluation of the measured urinary creatinine clearance (CrCL), the predicted creatinine clearance based on Cockcroft-Gault.
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
Stephen R. Ash, MD, FACP IU Health Arnett Lafayette, Indiana 2017
Section 2: Detection of CKD
- Higher SBP visit-to-visit variability (SBV) has been associated
Cancer & the Kidney Theory to Practice
Pharmacokinetics of Vancomycin in Adult Oncology Patients
Updates on Policy #38 Addressing Subjects with Non-Average Heights and Weights 2017 SWOG Fall Meeting BOG Siu Fun Wong, PharmD Co-Chair, Pharmaceutical.
Estimating Glomerular Filtration Rate In Overweight and Obese Malaysian Subjects Nor-Hayati S1, Soehardy Z1, Norella Kong CT1, Rohana AG2, Nor-Azmi K2,
From: A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation Ann Intern Med. 1999;130(6):
Chronic kidney disease in an inner London HIV Cohort
The MDRD Study.
From: Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate.
Fig. 1. Distribution of eGFR according to baseline SCr
Does the Beer’s Criteria Influence Prescribing for Geriatric Patients?
Renal Pharmacy Group Beginners Lectures 2018
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
A: Kaplan-Meier estimate of time to first LLA
Improving Carboplatin Dosing Based on Estimated GFR
Comparison of Drug Dosing Recommendations Based on Measured GFR and Kidney Function Estimating Equations  Lesley A. Stevens, MD, MS, Thomas D. Nolin,
Quiz Page July 2012 American Journal of Kidney Diseases
Drug Dose Adjustments in Patients With Renal Impairment
Improving Carboplatin Dosing Based on Estimated GFR
Serum 25(OH)D levels stratified by the presence or absence of nephropathy. Serum 25(OH)D levels stratified by the presence or absence of nephropathy. The.
Risk factors Odds ratio 95% CI p Age >75 (referent: age 46-60) 2.17
Area under the curve (AUC)–targeted dosing of carboplatin using either the Cockcroft–Gault formula or the Chronic Kidney Disease Epidemiology Collaboration.
Plots of average estimated and measured GFR vs
Presentation transcript:

Evaluation of the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (C-G) formulas in the Calvert equation for Carboplatin Dosing Whitney Jones, PharmD Candidate1; LeAnn B. Norris, PharmD, BCPS2; P. Brandon Bookstaver, PharmD, BCPS2; Richard Schulz, PhD2 1University of South Carolina College of Pharmacy, Columbia, SC; 2South Carolina College of Pharmacy, USC Campus, Columbia, SC

Background Carboplatin is a second generation platinum agent Used in the treatment of NSCLC 70% is excreted in the urine The Calvert equation Carboplatin dose = AUC (GFR+25) Standard method for carboplatin dose calculation1,2 Correlation between renal clearance and glomerular filtration rate (GFR)3,4 1Calvert AH, et al. Clin Oncol 1989;7:1748-56. 2Duffull SB, et al. Clin Pharmacokinet 1997; 33(3): 161-83. 3Calvert AH, et al. Cancer Chemother Pharmacol 1982; 9: 140-7. 4Herrington JD, et al. Cancer Chemother Pharmacol 2006;57:241-7.

Background C-G equation (original) Commonly used in the Calvert formula Inaccuracies in carboplatin dosing5 MDRD equation More accurate than the C-G equation (GFR < 60 ml/min) Sparse data is available in cancer patients and drug dosing6 Modified C-G (mC-G) equation Greater accuracy with CrCl < 50 mL/min and BMI < 257 Improves upon bias and precision of C-G equation8 5Ando Y, et al. Br J Cancer 1997;76:1067. 6Wright JG, et al. Br J Cancer 2001;84(4):452-9. 7Shoker A, et al. Clin Nephrol 2006;66(2):89-97. 8Rostoker G, et al. J Nephrol 2007;20:576-85.

Renal Clearance Equations Original C-G (C-G), ml/min CrCl = (140-age) x IBW / SCr x 72 (0.85 female) 6-variable MDRD formula, ml/min GFR/1.73m2 = 170 x (SCr -0.999) x (Age -0.176) x (0.762 female) x (1.180 A.A.) x (BUN -0.170) x (Alb.318) Modified C-G (mC-G), ml/min CrCl/1.73m2 = (140-age) x TBW / SCr x 72 (0.85 female)

Study Objective To determine whether a significant difference exists in comparison of renal function and carboplatin dosing using the original C-G, mC-G, and 6-variable MDRD formulas in a population of patients treated for non-small cell lung cancer.

Methods Retrospective, non-interventional study Conducted at a Veterans Administration Hospital (Columbia, SC) Inclusion Criteria: Age > 18 years Completion of at least one dose of carboplatin Exclusion Criteria: Any diagnosis other than NSCLC Albumin measurement > 1 month from first carboplatin dose Patients were not duplicated in this study

Endpoints Primary endpoints: Difference in estimate renal function (CrCl or GFR) between 3 study formulas Difference in calculated carboplatin doses using renal function estimates of 3 study formulas

Analysis Paired Student t tests were performed Intra-patient variability measured as clinical significance, defined as ≥ 20% difference Accuracy defined as +/- 30% difference in renal estimation (compared to C-G)

Results Table 1 Demographics n = 128 Gender Male 125 Female 3 Race Non-African American 79 African American 49 Characteristic Mean (+/-SD) Age, years 62.99 +/- 9.12 TBW, kg 78.88 +/- 20.93 BSA, m2 1.96 +/- 0.28 SCr, mg/dL 1 +/- 0.30 Albumin, g/dL 3.2 +/- 0.55

Results Evaluation of Carboplatin Clearance Calculations Mean Diff SD 95% CI P-value C-G v. mC-G 5.83 12.58 3.63 – 8.03 <0.001 C-G v. MDRD 4.73 24.13 0.511 – 8.95 0.028 mC-G v. MDRD -1.09 25.91 -5.63 – 3.44 0.634 Evaluation of Carboplatin Dose Calculations Mean Diff. SD 95% CI P-value C-G v. mC-G 6.05 109.6 -13.12 – 25.22 0.533 C-G v. MDRD 7.64 183.46 -24.45 – 39.73 0.648 mC-G v. MDRD 1.59 131.79 -21.47 – 24.64 0.892

Clinical Significance and Accuracy Discordance in 14.84% of doses when comparing C-G to mC-G Discordance in 46.09% of doses when comparing C-G to MDRD Accuracy (30%) of Renal Estimations Number % Achievement C-G vs. mC-G 3 3.13 C-G vs. MDRD 32 25

Discussion/Conclusions Differences exist between the C-G, mC-G, and 6-variable MDRD formulas Application of individual formulas could result in clinically significant carboplatin dosing modifications A prospective, controlled study would aid in determining the optimal formula for renal function estimations in carboplatin dosing Investigation of patient populations Correlation of carboplatin levels and renal function prediction

Evaluation of the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (C-G) formulas in the Calvert equation for Carboplatin Dosing Whitney Jones, PharmD Candidate1; LeAnn B. Norris, PharmD, BCPS2; P. Brandon Bookstaver, PharmD, BCPS2; Richard Schulz, PhD2 1University of South Carolina College of Pharmacy, Columbia, SC; 2South Carolina College of Pharmacy, USC Campus, Columbia, SC